Enhanced Oncolytic Virus Growth Method and Antitumor Agent

Publication ID: 24-11857584_0006_PTD

Published: October 28, 2025

Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Oncolytic Virus Growth Method and Antitumor Agent,” Published Technical Disclosure No. 24-11857584_0006_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857584_0006_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,584.

Summary of the Inventive Concept

The present inventive concept relates to a novel antitumor therapy using oncolytic viruses, specifically enhancing the antitumor effect of coxsackievirus through combination chemotherapy and optimized virus receptor expression.

Background and Problem Solved

The original patent disclosed a method for enhancing an antitumor effect of a coxsackievirus by administering oxaliplatin and the coxsackievirus to a subject in need thereof. However, the original method has limitations in terms of efficacy and resistance to oxaliplatin. The present inventive concept addresses these limitations by introducing combination chemotherapy and optimized virus receptor expression to enhance the antitumor effect of coxsackievirus.

Detailed Description of the Inventive Concept

The present inventive concept comprises methods for enhancing an antitumor effect of a coxsackievirus, promoting proliferation of a coxsackievirus, and enhancing an expression of a virus receptor of a cancer cell. The methods involve administering a combination of oxaliplatin and a second chemotherapeutic agent, culturing the coxsackievirus in the presence of a proteasome inhibitor, and administering a histone deacetylase inhibitor. The inventive concept also includes a system for treating oxaliplatin-resistant cancer comprising a coxsackievirus, an antimetabolite, and a third chemotherapeutic agent.

Novelty and Inventive Step

The present inventive concept introduces novel combinations of chemotherapeutic agents and optimized virus receptor expression, which are not obvious from the original patent. The use of a second chemotherapeutic agent, proteasome inhibitor, and histone deacetylase inhibitor in combination with oxaliplatin and coxsackievirus provides a synergistic effect in enhancing the antitumor effect of coxsackievirus.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include using different combinations of chemotherapeutic agents, varying the sequence and timing of administration, and incorporating additional agents to enhance the antitumor effect. Variations of the system for treating oxaliplatin-resistant cancer may include using different types of viruses, antimetabolites, and chemotherapeutic agents.

Potential Commercial Applications and Market

The present inventive concept has potential commercial applications in the development of novel antitumor therapies, particularly for treating oxaliplatin-resistant cancer. The target market includes pharmaceutical companies, research institutions, and hospitals specializing in cancer treatment.

CPC Classifications

Section	Class	Group
A	A61	A61K35/768
A	A61	A61K31/282
A	A61	A61K31/4745
A	A61	A61K31/513
A	A61	A61P35/00
C	C12	C12N7/00
C	C12	C12N2770/32332

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Oncology and virology, specifically oncolytic virus therapy with a focus on cancer treatment methods involving viral agents and chemotherapeutic combinations. A PHOSITA would have advanced training in molecular biology, cancer therapeutics, and viral engineering with expertise in combinatorial treatment strategies

Person of Ordinary Skill (PHOSITA) Profile

A medical researcher or oncologist with advanced degrees (PhD/MD) specializing in cancer therapeutics, familiar with viral vector technologies, chemotherapy mechanisms, and experimental treatment optimization techniques

Obviousness Rationale

A PHOSITA would recognize that extending the source patent's coxsackievirus and oxaliplatin combination represents a predictable variation in cancer treatment. The disclosed modifications involve standard chemotherapeutic agents and established techniques for enhancing viral therapeutic efficacy. The incremental additions of proteasome inhibitors, histone deacetylase inhibitors, and alternative chemotherapy agents represent logical extensions of the original therapeutic approach.

Obvious Combinations & Variations

Source Patent Element

Coxsackievirus administration with oxaliplatin for antitumor effect

PTD Variation

Adding cisplatin or carboplatin as a second chemotherapeutic agent

Obviousness Reasoning

Platinum-based chemotherapeutics are known interchangeable agents with predictable mechanisms of action, representing a routine optimization for a PHOSITA

Source Patent Element

Treatment of oxaliplatin-resistant cancer

PTD Variation

Incorporating proteasome inhibitors like bortezomib to enhance viral proliferation

Obviousness Reasoning

Proteasome inhibitors are well-established cellular modulators that a PHOSITA would recognize as a potential method to enhance viral replication and therapeutic efficacy

Source Patent Element

Enhancing virus receptor expression

PTD Variation

Using histone deacetylase inhibitors to modulate cellular receptor dynamics

Obviousness Reasoning

Epigenetic modulation techniques are standard approaches for enhancing cellular receptor expression, representing a predictable optimization strategy

Source Patent Element

Coxsackievirus antitumor method

PTD Variation

Adding docetaxel or paclitaxel as complementary chemotherapeutic agents

Obviousness Reasoning

Combining multiple chemotherapeutic agents is a standard oncological approach for enhancing treatment efficacy, representing a logical extension of existing therapeutic strategies

Source Patent Element

Oxaliplatin-resistant cancer treatment

PTD Variation

Specifying patient population as having undergone prior chemotherapy

Obviousness Reasoning

Defining specific patient subpopulations is a routine method of refining therapeutic approaches, representing a predictable clinical optimization

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857584, the present publication demonstrates that the claimed variations in oncolytic virus therapy represent obvious extensions of the prior art, utilizing standard combinatorial techniques and predictable modifications within the ordinary skill of practitioners in oncological and virological research. The disclosed methods would have been obvious to a person of ordinary skill in the art at the time of invention, rendering potential claims directed to these variations unpatentable under 35 U.S.C. § 103.

Original Patent Information

Patent Number	US 11,857,584
Title	Oncolytic virus growth method and antitumor agent
Assignee(s)	KABUSHIKI KAISHA YAKULT HONSHA